Gastroenterology — MCQs

Gastroenterology Indian Medical PG Practice Questions and MCQs

Question 781: What is the best medical therapy for radiation proctitis among the following?

A. Formalin application
B. Sucralfate enema (Correct Answer)
C. 5-Aminosalicylic acid enema
D. Steroid enema

Explanation: **Explanation:** Radiation proctitis is a common complication following pelvic radiotherapy (e.g., for prostate or cervical cancer). It is categorized into acute (within 3 months) and chronic phases. **Why Sucralfate Enema is the Correct Answer:** Sucralfate is a basic aluminum salt of sulfated sucrose. When administered as an enema, it binds to the injured mucosa and forms a protective physical barrier (a "paste") over the friable, telangiectatic vessels. It also stimulates the local production of prostaglandins and epidermal growth factor, which promotes mucosal healing. Clinical trials have demonstrated that **sucralfate enemas are superior to anti-inflammatory agents** (like steroids or 5-ASA) in reducing rectal bleeding and improving mucosal appearance in chronic radiation proctitis. **Analysis of Incorrect Options:** * **Formalin application (Option A):** While highly effective for refractory bleeding, it is a **chemical cauterization** procedure, not a "medical therapy." It is typically reserved for cases where enemas fail. * **5-Aminosalicylic acid (5-ASA) enema (Option C):** Although used in Inflammatory Bowel Disease (IBD), 5-ASA has shown **minimal to no benefit** in radiation proctitis because the underlying pathology is ischemia and fibrosis, not primary idiopathic inflammation. * **Steroid enema (Option D):** Similar to 5-ASA, steroids are generally **ineffective** for chronic radiation proctitis [1] as the condition is characterized by obliterative endarteritis rather than active neutrophilic inflammation. **NEET-PG High-Yield Pearls:** * **Pathology:** Chronic radiation proctitis is characterized by **obliterative endarteritis** leading to mucosal ischemia and neovascularization (telangiectasias). * **First-line Medical Therapy:** Sucralfate enemas. * **First-line Interventional Therapy:** Argon Plasma Coagulation (APC) is the most common and effective endoscopic treatment. * **Refractory Cases:** Formalin (4% solution) application or Hyperbaric Oxygen Therapy.

Question 782: What is the most common extraintestinal manifestation of Inflammatory Bowel Disease?

A. Dermatological
B. Rheumatological (Correct Answer)
C. Metabolic bone disease
D. Hepatobiliary

Explanation: **Explanation:** Extraintestinal manifestations (EIMs) occur in approximately 25–40% of patients with Inflammatory Bowel Disease (IBD). **Rheumatological manifestations** are the most common EIM, affecting up to 30% of patients [1]. These are broadly categorized into: 1. **Peripheral Arthritis:** Usually non-deforming and asymmetrical. Type I (pauciarticular) correlates with bowel activity, while Type II (polyarticular) runs an independent course. 2. **Axial Arthropathy:** Includes ankylosing spondylitis and sacroiliitis, which are HLA-B27 associated and progress independently of the bowel disease [1], [2]. **Analysis of Incorrect Options:** * **Dermatological (Option A):** These are the second most common EIMs. Key examples include Erythema Nodosum (correlates with bowel activity) and Pyoderma Gangrenosum (often runs an independent course). * **Metabolic Bone Disease (Option C):** While Osteoporosis and Osteomalacia are common due to chronic corticosteroid use and malabsorption (especially in Crohn’s), they are considered secondary complications rather than the primary inflammatory EIM. * **Hepatobiliary (Option D):** These are less frequent but highly specific. Primary Sclerosing Cholangitis (PSC) is the most notable, occurring more commonly in Ulcerative Colitis than in Crohn’s Disease. **High-Yield Clinical Pearls for NEET-PG:** * **Most common EIM overall:** Peripheral Arthritis. * **Most common ocular manifestation:** Episcleritis (correlates with bowel activity); Uveitis is more severe and requires urgent referral [2]. * **HLA Association:** HLA-B27 is strongly linked to axial involvement in IBD [2]. * **PSC and UC:** 70–80% of patients with PSC have underlying UC, but only 5% of UC patients develop PSC.

Question 783: All of the following are true about Zollinger-Ellison syndrome, except?

A. Recurrent peptic ulcers
B. High levels of gastrin
C. Pyloric antral tumor (Correct Answer)
D. Basal acid output more than 15 mEq/L

Explanation: Zollinger-Ellison Syndrome (ZES) is caused by a gastrin-secreting neuroendocrine tumor known as a **Gastrinoma**. **Why Option C is the correct answer (The Exception):** Gastrinomas are most commonly located in the **"Gastrinoma Triangle"** (Passaro’s Triangle), which is bounded by the junction of the cystic and common bile ducts, the junction of the second and third portions of the duodenum, and the junction of the neck and body of the pancreas. The most common site for a primary gastrinoma is the **duodenum** (40-50%), followed by the **pancreas**. They are **not** typically found in the pyloric antrum of the stomach. **Analysis of other options:** * **Option A (Recurrent peptic ulcers):** True. Excessive gastrin causes massive hypersecretion of gastric acid, leading to multiple, refractory, and recurrent ulcers, often in atypical locations like the distal duodenum or jejunum. * **Option B (High levels of gastrin):** True. Hypergastrinemia (>1000 pg/mL) is the biochemical hallmark of ZES. * **Option D (Basal acid output >15 mEq/L):** True. A Basal Acid Output (BAO) >15 mEq/h (in patients with an intact stomach) is a diagnostic criterion for ZES. **NEET-PG High-Yield Pearls:** * **Screening Test:** Fasting Serum Gastrin (FSG) levels (should be >10 times the upper limit). * **Confirmatory Test:** Secretin Stimulation Test (Secretin paradoxically increases gastrin levels in ZES). * **Association:** Approximately 25% of ZES cases are associated with **Multiple Endocrine Neoplasia type 1 (MEN1)**. * **Most common symptom:** Abdominal pain (due to PUD), followed by **diarrhea** (due to mucosal damage and inactivation of pancreatic enzymes by low pH).

Question 784: Crohn's disease is associated with which one of the following infectious agents?

A. Clostridium difficile (Correct Answer)
B. Mycobacterium paratuberculosis
C. Cytomegalovirus (CMV)
D. Mycoplasma

Explanation: ### Explanation **Correct Answer: A. Clostridium difficile** **Why it is correct:** In the context of Inflammatory Bowel Disease (IBD), *Clostridium difficile* (now *Clostridioides difficile*) is the most significant infectious agent associated with disease exacerbations. Patients with Crohn’s disease and Ulcerative Colitis have an altered gut microbiome and are often on immunosuppressants or antibiotics, making them highly susceptible to *C. difficile* infection (CDI) [1]. CDI can mimic or trigger a flare-up of Crohn’s disease, leading to increased morbidity and hospitalization. Current clinical guidelines recommend screening for *C. difficile* in all IBD patients presenting with an acute relapse. **Why the other options are incorrect:** * **B. Mycobacterium paratuberculosis:** While the "Mycobacterium theory" suggested a causal link between *M. avium paratuberculosis* (MAP) and Crohn’s due to its role in Johne’s disease in cattle, extensive clinical trials with anti-mycobacterial therapy have failed to prove a definitive etiologic association in humans. * **C. Cytomegalovirus (CMV):** CMV is more commonly associated with **Ulcerative Colitis**, particularly in cases of "steroid-refractory" colitis. While it can occur in Crohn's, it is not the primary infectious agent classically associated with general Crohn's exacerbations in the same frequency as *C. difficile* [2]. * **D. Mycoplasma:** There is no established clinical or pathological association between Mycoplasma species and the pathogenesis or exacerbation of Crohn’s disease. **NEET-PG High-Yield Pearls:** * **Most common infection triggering IBD flare:** *C. difficile*. * **Diagnosis:** Stool PCR for toxin genes or Enzyme Immunoassay (EIA) for toxins A and B. * **Treatment in IBD:** Oral Vancomycin or Fidaxomicin is preferred over Metronidazole. * **Skip Lesions & Transmural Inflammation:** Key pathological hallmarks of Crohn’s (unlike the continuous, mucosal involvement in UC) [2]. * **ASCA vs. p-ANCA:** Crohn’s is typically **ASCA positive**, while UC is **p-ANCA positive**.

Question 785: Which of the following describes non-progressive contractions of the esophagus?

A. Primary
B. Secondary
C. Tertiary (Correct Answer)
D. Quaternary

Explanation: **Explanation:** The correct answer is **Tertiary contractions**. Esophageal motility is categorized into three distinct types based on the trigger and the nature of the wave: 1. **Tertiary Contractions (Correct):** These are non-propulsive, non-progressive, and uncoordinated waves that occur simultaneously at different levels of the esophagus [2]. They are considered dysfunctional and do not aid in bolus transport. On a barium swallow, they produce the characteristic **"Corkscrew esophagus"** or **"Rosary bead esophagus."** They are commonly seen in conditions like Diffuse Esophageal Spasm (DES) and in the elderly ("Presbyesophagus") [2]. 2. **Primary Contractions (Incorrect):** These are normal, progressive peristaltic waves initiated by the act of swallowing (deglutition). They travel from the upper esophagus to the Lower Esophageal Sphincter (LES) to move the food bolus. 3. **Secondary Contractions (Incorrect):** These are also progressive and normal. They are not triggered by swallowing but by local distension of the esophagus (e.g., a retained food bolus or acid reflux). They serve as a "clearing" mechanism. 4. **Quaternary (Incorrect):** This is not a standard physiological term used to describe esophageal motility patterns. **High-Yield Clinical Pearls for NEET-PG:** * **Diffuse Esophageal Spasm (DES):** Presents with intermittent chest pain and dysphagia [2]. Manometry shows high-amplitude, non-peristaltic (tertiary) contractions [2]. * **Nutcracker Esophagus:** Characterized by high-pressure (over 180 mmHg) but **progressive** (peristaltic) contractions [2]. * **Barium Swallow Tip:** If you see "Corkscrew esophagus," think Tertiary contractions/DES [1]. If you see "Bird’s beak appearance," think Achalasia Cardia [1].

Question 786: Which of the following statements regarding ulcerative colitis is true?

A. Smoking has a protective effect. (Correct Answer)
B. Smoking does not have a protective effect.
C. There is no relation to smoking.
D. Smoking causes relapses.

Explanation: The relationship between smoking and Inflammatory Bowel Disease (IBD) is a classic high-yield topic for NEET-PG. In **Ulcerative Colitis (UC)**, smoking is famously associated with a **protective effect** [1]. **1. Why Option A is correct:** Epidemiological studies consistently show that UC is primarily a disease of non-smokers and ex-smokers. The risk of developing UC is significantly lower in active smokers compared to those who have never smoked. Furthermore, patients who smoke often experience a milder disease course with fewer relapses and a decreased need for colectomy. While the exact mechanism is not fully understood, it is hypothesized that nicotine or other components in tobacco smoke increase colonic mucus production and modify the immune response in the gut mucosa [1]. **2. Why other options are incorrect:** * **Options B & C:** These are incorrect because there is a well-documented, statistically significant inverse relationship between smoking and UC. * **Option D:** Smoking does not cause relapses in UC; in fact, many patients report a **flare-up of symptoms immediately after smoking cessation** [3]. **Clinical Pearls for NEET-PG:** * **The IBD Paradox:** While smoking is **protective in Ulcerative Colitis**, it is a major **risk factor for Crohn’s Disease**, where it increases the risk of strictures, fistulae, and post-operative recurrence. * **Appendectomy:** Similar to smoking, a history of appendectomy at a young age (for true appendicitis) is also protective against the development of Ulcerative Colitis. * **Treatment:** Although smoking is protective, it is never recommended as a therapy due to its systemic health risks. However, nicotine patches have been studied as an adjunctive treatment for active UC with varying results [2].

Question 787: Which of the following does not lead to chronic liver disease?

A. Hepatitis A (Correct Answer)
B. EBV
C. Infectious mononucleosis
D. Hepatitis B

Explanation: **Explanation:** The core concept tested here is the natural history of viral hepatitides. **Hepatitis A Virus (HAV)** is an RNA virus transmitted via the fecal-oral route. It causes acute, self-limiting hepatitis but **never** progresses to chronic liver disease or a carrier state [1]. Once the acute infection resolves, the patient develops lifelong immunity (anti-HAV IgG) [1]. **Analysis of Options:** * **Hepatitis A (Correct):** As mentioned, HAV (and Hepatitis E, except in immunocompromised/transplant patients) does not cause chronicity [1]. * **Hepatitis B (Incorrect):** HBV is a classic cause of chronic liver disease [2]. The risk of chronicity is inversely proportional to age (90% in neonates, <5% in adults). * **EBV / Infectious Mononucleosis (Incorrect):** While Epstein-Barr Virus (EBV) primarily causes acute hepatitis as part of the Infectious Mononucleosis syndrome, it is a known cause of **chronic active hepatitis** and can lead to cirrhosis in rare, severe cases or in patients with Chronic Active EBV infection (CAEBV) [1]. *Note: In many standard MCQ formats, EBV is considered a potential cause of chronic inflammation, making HAV the "most correct" answer as it has zero chronicity potential.* **High-Yield Clinical Pearls for NEET-PG:** * **Vowels to the Bowels:** Hepatitis **A** and **E** are fecal-oral and do not cause chronic disease (Exception: HEV Genotype 3 in transplant patients). * **Consonants to the Blood:** Hepatitis **B, C, and D** are parenteral and cause chronic liver disease/cirrhosis [1]. * **Hepatitis B:** The most common cause of Hepatocellular Carcinoma (HCC) worldwide. * **Hepatitis C:** The most common cause of chronic liver disease leading to liver transplantation in the West [3].

Question 788: Hepatic encephalopathy is caused by an increase of -

A. Urea
B. Glutamate
C. Ammonia (Correct Answer)
D. Fatty acid

Explanation: **Explanation:** **Hepatic Encephalopathy (HE)** is a reversible neuropsychiatric syndrome occurring in patients with acute or chronic liver failure [1]. It is primarily caused by the liver's inability to detoxify nitrogenous waste products [2]. **1. Why Ammonia is Correct:** Ammonia ($NH_3$) is the primary neurotoxin implicated in HE [1]. It is produced by intestinal bacteria through the breakdown of proteins and urea. In a healthy liver, ammonia is converted into urea via the **Urea Cycle**. In liver failure or portosystemic shunting, ammonia bypasses the liver and crosses the blood-brain barrier [2]. In the brain, astrocytes attempt to detoxify ammonia by combining it with **Glutamate** to form **Glutamine** (via Glutamine Synthetase). The resulting osmotic buildup of glutamine leads to astrocyte swelling and cerebral edema. **2. Why Other Options are Incorrect:** * **Urea:** This is the non-toxic end product of ammonia metabolism. High urea (Uremia) causes encephalopathy in renal failure, not hepatic failure. * **Glutamate:** Glutamate is an excitatory neurotransmitter. In HE, glutamate levels actually **decrease** because it is consumed to produce glutamine. * **Fatty Acids:** While short-chain fatty acids may play a synergistic role in neurotoxicity, they are not the primary causative agent. **NEET-PG High-Yield Pearls:** * **Clinical Sign:** **Asterixis** (flapping tremors) is the hallmark of Grade II HE. * **EEG Finding:** Characteristic **triphasic waves**. * **Treatment of Choice:** **Lactulose** (acidifies the gut to convert $NH_3$ to non-absorbable $NH_4^+$) and **Rifaximin** (reduces ammonia-producing gut bacteria). * **Precipitating Factors:** GI bleed (increases protein load), infections (SBP), hypokalemia, and constipation.

Question 789: Which of the following is NOT a complication of enteral feeding?

A. Diarrhea
B. Constipation
C. Hypoglycemia (Correct Answer)
D. Aspiration pneumonia

Explanation: Enteral nutrition (EN) involves delivering nutrients directly into the gastrointestinal tract. While it is generally safer than parenteral nutrition, it is associated with specific gastrointestinal, mechanical, and metabolic complications [1]. **Hypoglycemia** is not a standard complication of enteral feeding. In fact, **hyperglycemia** is the common metabolic complication seen in patients receiving EN, often due to the high carbohydrate load, underlying stress response, or insulin resistance in critically ill patients. Hypoglycemia typically only occurs if enteral feeding is abruptly stopped without adjusting insulin doses or in cases of "dumping syndrome" (reactive hypoglycemia) following gastric surgery. **Diarrhea (A):** The most common gastrointestinal complication of EN (occurring in up to 30% of patients). It is usually caused by high osmolarity of the formula, rapid infusion rates, or concomitant antibiotic use (e.g., *C. difficile*). **Constipation (B):** Frequently occurs due to low fiber content in standard formulas, inadequate fluid intake, or the use of opioid medications in hospitalized patients. **Aspiration Pneumonia (D):** The most serious respiratory complication. Risk factors include a supine position (head of bed <30°), high gastric residual volumes, and impaired gag reflex. **Refeeding Syndrome:** A life-threatening metabolic complication occurring when feeding is restarted in severely malnourished patients. Look for **Hypophosphatemia** (hallmark), hypokalemia, and hypomagnesemia. **Prevention of Aspiration:** Keep the head of the bed elevated to **30–45 degrees**. **Preferred Route:** Enteral feeding is always preferred over parenteral feeding ("If the gut works, use it") because it maintains the intestinal mucosal barrier and prevents bacterial translocation.

Question 790: Which of the following conditions is associated with mucinous ascites?

A. Stomach carcinoma (Correct Answer)
B. Tuberculosis
C. Nephrotic syndrome
D. Cirrhosis

Explanation: The explanation with [1], [2] inline citations added: **Mucinous ascites** (also known as gelatinous ascites) occurs when mucin-producing cells seed the peritoneal cavity, leading to the accumulation of thick, semi-solid fluid. This condition is most commonly associated with **Pseudomyxoma Peritonei**, which typically arises from mucinous tumors of the **appendix** or **ovary**. However, among the given options, **Stomach carcinoma** (specifically the signet-ring cell type or mucinous adenocarcinoma) is a well-recognized cause of peritoneal carcinomatosis that can lead to mucinous ascites [1]. **Analysis of Options:** * **Stomach carcinoma (Correct):** Advanced gastric malignancies can spread to the peritoneum. If the primary tumor is a mucinous adenocarcinoma, it secretes abundant mucus into the peritoneal space, resulting in mucinous ascites. * **Tuberculosis:** Characteristically causes **exudative ascites** with high protein (>3g/dL), high SAAG (<1.1), and elevated Adenosine Deaminase (ADA) levels [2]. The fluid is typically straw-colored, not mucinous. * **Nephrotic syndrome:** Causes **transudative ascites** due to severe hypoalbuminemia (decreased oncotic pressure). The fluid is clear or serous [2]. * **Cirrhosis:** The most common cause of ascites, resulting in **transudative fluid** (SAAG >1.1) due to portal hypertension [2]. **NEET-PG High-Yield Pearls:** * **Pseudomyxoma Peritonei:** Classically described as "Jelly Belly." The most common primary site is the **Appendix**. * **SAAG (Serum-Ascites Albumin Gradient):** The most reliable marker to differentiate portal hypertensive (>1.1) from non-portal hypertensive (<1.1) causes [2]. * **Chylous Ascites:** Milky fluid (high triglycerides) seen in lymphomas or thoracic duct obstruction. * **Signet-ring cells:** Pathognomonic histological finding in certain gastric cancers that can lead to Krukenberg tumors and mucinous spread.

Practice by Chapter

Esophageal Disorders

Practice Questions

Peptic Ulcer Disease

Practice Questions

Inflammatory Bowel Disease

Practice Questions

Irritable Bowel Syndrome

Practice Questions

Malabsorption Syndromes

Practice Questions

Pancreatitis (Acute and Chronic)

Practice Questions

Gastrointestinal Bleeding

Practice Questions

Liver Diseases and Cirrhosis

Practice Questions

Viral Hepatitis

Practice Questions

Biliary Tract Disorders

Practice Questions

Gastrointestinal Motility Disorders

Practice Questions

Gastrointestinal Malignancies

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free